Globus Medical, Inc. GMED continues to benefit from the robust demand for its Musculoskeletal Solutions products. Following the NuVasive merger, the combined company has formed a global ...

The deal is expected to close in late Q2 2025, subject to Nevro shareholder and regulatory approval.Globus Medical also reaffirmed its guidance for 2025 net sales of $2.66B to $2.69B and non-GAAP ...

Globus Medical closed 2024 on a strong note with record financial performance, driven by sales growth, innovative product launches, and strategic acquisitions. The integration of Nevro Corporation ...

As previously announced on February 6, given the pending acquisition of Nevro (NVRO) by Globus Medical, Nevro is not issuing FY25 guidance, nor ...

2025 Financial Guidance and Fourth-Quarter 2024 Earnings Conference Call and Webcast As previously announced on February 6, 2025, given the pending acquisition of Nevro by Globus Medical ...

Reports Q4 revenue $105.5M, consensus $102.61M. Cash, cash equivalents and short-term investments totaled $292.5M as of December 31, 2024, an ...

Globus Medical's results underscore a strong quarter ... This outlook could improve further if the pending acquisition of Nevro (purchased for $250 million earlier this month) is finalized ...